A significant portion of the population, including 20% of the US and 34% globally, possesses a specific SNP, increasing the risk of obesity, insulin resistance, and metabolic syndrome. This SNP influences the lifelong number of fat cells by an unknown mechanism. We have discovered a new pathway through which this SNP affects the differentiation of stem cells into fat cells. Using our predictive animal model, we aim to develop and validate biologics to inhibit this fat formation pathway, addressing a major genetic risk factor for childhood obesity leading to type 2 diabetes and metabolic syndrome in adults. We are seeking funding to advance this therapeutic initiative.